Loading...
•
Mar 31
•/
AstraZeneca Q1 2025 Earnings Report
AstraZeneca delivered strong growth with a 10% revenue increase and robust clinical pipeline progress.
Key Takeaways
AstraZeneca posted a strong Q1 2025 with double-digit revenue growth driven by Oncology and BioPharmaceuticals, alongside five positive Phase III study readouts and expanded US manufacturing investments.
Total revenue rose 10% at constant exchange rates to $13.588 billion.
Reported EPS was $1.88, while Core (Adj.) EPS increased to $2.49.
Growth achieved across all major geographic regions.
Strong clinical pipeline progress with five positive Phase III readouts.
AstraZeneca
AstraZeneca
Forward Guidance
AstraZeneca reaffirmed its FY2025 guidance, expecting a high single-digit revenue increase and a low double-digit Core EPS growth at constant exchange rates.
Positive Outlook
- Total Revenue expected to increase by a high single-digit percentage.
- Core EPS expected to grow by a low double-digit percentage.
- Five positive Phase III study readouts bolster future growth.
- Significant US manufacturing and R&D investments planned.
- New regulatory approvals and submissions across key regions.
Challenges Ahead
- Potential low single-digit adverse impact from currency exchange rates.
- Ongoing investigations and compliance matters in China.
- Continued investments increasing R&D and SG&A expenses.
- Dependence on positive clinical trial outcomes for future pipeline success.
- Potential fines related to unpaid importation taxes in China.